Evaluation of high-risk factors and the diagnostic value of alpha-fetoprotein in the stratification of primary liver cancer

doi:10.12998/wjcc.v10.i26.9264

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4799)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-9) series.

Item

Count

PDF

206

WORD

HTML

2395

Figures (1-2)

445

Tables (1-9)

341

Sum=3465

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

352

Download

982

Sum=1334

Sep 16, 2022 (publication date) through Feb 11, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Sep 16, 2022; 10(26): 9264-9275
Published online Sep 16, 2022. doi: 10.12998/wjcc.v10.i26.9264

Table 1 Influence of high-risk factors on primary liver cancer stratified by Child-Pugh score

Factors	Criterion: Child-Pugh score			Statistics	P value
Factors	A	B	C	Statistics	P value
Male (%)	40 (76.9)	61 (77.2)	16 (76.9)	0.06	0.814
Age (yr)	59.40 ± 10.18	62.83 ± 9.85	58.50 ± 7.20	2.78	0.065
History of smoking (%)	16 (30.2)	22 (27.8)^a	12 (60.0)	7.74	0.021
History of drinking (%)	13 (24.5)^a	26 (32.9)	11 (55.0)	6.11	0.047
HBsAg (+) (%)	38 (71.7)	56 (70.9)	14 (70.0)	0.02	0.989
HCV-Ag (+) (%)	3 (5.7)	5 (6.3)	0 (0.0)	1.31	0.520
Non-alcoholic fatty liver (%)	9 (17.0)	18 (22.8)	1 (5.0)	3.47	0.176

^aCompared with “C”, P < 0.0167. HBsAg: Hepatitis B virus antigen; HCV: Hepatitis C virus.

Table 2 Influence of high-risk factors on primary liver cancer stratified by clinical stage of cirrhosis

Factors	Criterion: Clinical stage of cirrhosis			Statistics	P value
Factors	No cirrhosis	Compensated	Decompensated	Statistics	P value
Male (%)	99 (72.3)	33 (78.6)	84 (77.1)	1.08	0.582
Age (yr)	62.93 ± 11.85	61.21 ± 1.58	60.93 ± 9.04	1.14	0.322
History of smoking (%)	47 (34.3)	13 (30.2)	37 (33.9)	0.26	0.880
History of drinking (%)	50 (36.5)	11 (26.2)	39 (35.8)	1.59	0.451
HBsAg (+) (%)	46 (33.6)	32 (76.2) ^a	76 (69.1) ^a	41.27	< 0.001
HCV-Ag (+) (%)	9 (6.6)	2 (4.8)	6 (5.5)	0.25	0.883
Non-alcoholic fatty liver (%)	39 (28.5)	9 (21.4)	19 (17.3)	4.38	0.112

^aCompared with “No cirrhosis”, P < 0.0167. HBsAg: Hepatitis B virus antigen; HCV: Hepatitis C virus.

Table 3 Influence of high-risk factors on primary liver cancer stratified by pathological classification of tumor size

Factors	Criterion: Pathological classification of tumor size					Statistics	P value
Factors	Small	Medium	Large	Massive	Diffuse	Statistics	P value
Male (%)	30 (68.2)	17 (70.8)	30 (66.7)	22 (75.9)	117 (80.1)	5.05	0.283
Age (yr)	62.86 ± 9.03	59.45 ± 10.43	61.86 ± 8.86	57.79 ± 11.69	63.03 ± 11.75	1.75	0.139
History of smoking (%)	9 (20.5)	9 (37.5)	12 (26.7)	12 (41.4)	55 (37.4)	6.29	0.179
History of drinking (%)	10 (22.7)	8 (33.3)	14 (31.1)	11 (37.9)	57 (38.8)	4.28	0.370
HBsAg (+) (%)	20 (45.5)	14 (58.3)	23 (51.1)	14 (48.3)	83 (56.5)	2.30	0.680
HCV-Ag (+) (%)	3 (6.8)	1 (4.2)	4 (8.9)	2 (6.9)	7 (4.8)	1.32	0.858
Cirrhosis (%)	31 (70.5)	17 (70.0)	20 (44.4)	10 (34.5)^a	74 (50.3)	14.15	0.007
Non-alcoholic fatty liver (%)	10 (22.7)	7 (29.2)	7 (15.6)	7 (24.1)	36 (24.5)	2.11	0.715

^aCompared with “Small”, P < 0.005. HBsAg: Hepatitis B virus antigen; HCV: Hepatitis C virus.

Table 4 Influence of high-risk factors on primary liver cancer stratified by Barcelona stage

Factors	Criterion: Barcelona stage				Statistics	P value
Factors	A stage	B stage	C stage	D stage	Statistics	P value
Male (%)	36 (67.9)	42 (76.4)	51 (75.0)	87 (77.7)	1.90	0.594
Age (yr)	60.25 ± 11.57	65.15 ± 12.40	62.50 ± 11.28	60.80 ± 9.05	2.53	0.057
History of smoking (%)	14 (26.4)	20 (36.4)	23 (33.8)	40 (35.4)	1.58	0.664
History of drinking (%)	15 (28.3)	16 (29.1)	28 (41.2)	41 (36.3)	3.11	0.375
HBsAg (+) (%)	21 (39.6)^a	24 (43.6^a	31 (45.6)^a	78 (69.0)	18.90	< 0.001
HCV-Ag (+) (%)	4 (7.5)	4 (7.3)	3 (4.4)	6 (5.3)	0.79	0.852
Cirrhosis (%)	11 (20.8)^a	13 (23.6)^a	15 (22.1)^a	113 (100.0)	167.33	< 0.001
Non-alcoholic fatty liver (%)	14 (26.4)	18 (32.7)	15 (22.1)	20 (17.7)	5.08	0.166

^aCompared with “D”, P < 0.0083. HBsAg: Hepatitis B virus antigen; HCV: Hepatitis C virus.

Table 5 Analysis of alpha-fetoprotein level and diagnosis positive rate in patients with primary liver cancer, chronic hepatitis and cirrhosis

Group	n	Men:Women	Age (mean ± S)	AFP (ng/mL)	Diagnosis positive rate, %
Chronic hepatitis B	217	157:60	59.85 ± 7.25	2.77 (1.67, 5.15)^a	1.4^b
Cirrhosis	279	204:75	60.99 ± 9.91	3.26 (1.74, 9.80)^a	4.7^b
PLC	289	216:73	61.92 ± 10.84	63.69 (3.28, 1210.00)	35.6
Statistics		0.536	2.869	121.974	147.565
P value		0.765	0.057	< 0.001	< 0.001

^aCompared with “PLC group”, P < 0.05.

^bCompared with “PLC group”, P < 0.0167. AFP: Alpha-fetoprotein; PLC: Primary liver cancer.

Table 6 Alpha-fetoprotein expression levels in primary liver cancer by different standards

Layering standard	Group	AFP (ng / mL)	F	P value
Cirrhosis clinical stage			10.03	0.007
	No cirrhosis	7.32 (2.28, 7.32)
	Compensated cirrhosis	267.40 (12.56, 1210.00)^a		0.004
	Decompensated cirrhosis	130.60 (6.69, 1210.00)^a		0.005
Child-Pugh classification			0.26	0.774
	A grade	461.16 ± 546.16
	B grade	516.74 ± 534.18
	C grade	549.64 ± 561.80
Classification of tumor size			21.70	< 0.001
	Small liver cancer	4.54 (1.78, 99.19)
	Medium liver cancer	12.56 (2.66, 521.65)
	Large liver cancer	17.58 (2.10, 782.25)
	Massive liver cancer	249.90 (4.14, 1210.00)
	Diffuse liver cancer	267.40 (3.69, 1210.00)^b		0.007
Barcelona stage			8.56	0.036
	Phase A	3.76 (1.78, 478.95)
	Phase B	103.90 (3.17, 1149.50)
	Phase C	111.90 (3.18, 1210.00)
	Phase D	116.25 (6.59, 1210.00)^c		0.009

^aCompared with “no cirrhosis”, P < 0.05.

^bCompared with “small liver cancer”, P < 0.05.

^cCompared with “Phase A”, P < 0.05. AFP: Alpha-fetoprotein.

Table 7 Analysis of diagnostic value of alpha-fetoprotein for primary liver cancer with different criteria

Layering standard	Group	AUC	Std.Error	P value	95%CI	Sensitivity, %	Specificity, %
Child-Pugh classification	A grade	0.759	0.0424	< 0.0001	(0.721, 0.794)	62.26	84.68
	B grade	0.847	0.0279	< 0.0001	(0.815, 0.875)	77.22	81.45
	C grade	0.821	0.0575	< 0.0001	(0.785, 0.853)	75.00	81.25
Cirrhosis clinical stage	No	0.647	0.0303	< 0.0001	(0.608, 0.684)	38.69	94.56
	Compensated cirrhosis	0.846	0.0369	< 0.0001	(0.813, 0.875)	78.57	81.05
	Decompensated cirrhosis	0.800	0.0276	< 0.0001	(0.766, 0.8310)	69.09	83.47
Classification of tumor size	Small	0.595	0.0514	0.0642	(0.552, 0.637)	38.64	84.68
	Medium	0.684	0.0636	0.0038	(0.642, 0.724)	66.67	73.39
	Large	0.675	0.0520	0.0008	(0.634, 0.714)	66.67	71.98
	Massive	0.805	0.0411	< 0.0001	(0.769, 0.838)	51.72	96.17
	Diffuse	0.785	0.0257	< 0.0001	(0.751, 0.816)	62.59	90.93
Barcelona stage	Phase A	0.592	0.0481	0.0547	(0.550, 0.634)	30.19	96.17
	Phase B	0.741	0.0415	< 0.0001	(0.703, 0.778)	52.73	90.93
	Phase C	0.731	0.0403	< 0.0001	(0.692, 0.767)	52.94	93.35
	Phase D	0.799	0.0271	< 0.0001	(0.765, 0.830)	68.14	83.47

AUC: Area under the curve.

Table 8 Evaluation of four indicators for diagnosing small liver cancer alone and in combination

Diagnostic indicators	AUC	Sensitivity, %	Specificity, %	Std.Error	95%CI	Z	P value
AFP	0.595	38.64	84.68	0.0519	(0.552, 0.632)	1.93	0.067
CEA	0.649	52.27	75.22	0.0461	(0.589, 0.706)	3.23	0.0013
CA-199	0.719	81.82	66.18	0.0467	(0.671, 0.763)	4.69	< 0.0001
GGT	0.728	77.27	56.89	0.0390	(0.671, 0.780)	5.84	< 0.0001
Combined diagnosis	0.810	68.18	79.56	0.0349	(0.758, 0.855)	8.90	< 0.0001

AUC: Area under the curve; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA 19-9: Carbohydrate antigen 19-9; GGT: Gamma-glutamyl transferase.

Table 9 Evaluation of the four indicators for the diagnosis of Barcelona Clinic Liver Cancer stage A liver cancer alone and in combination

Diagnostic indicators	AUC	Sensitivity, %	Specificity, %	Std.Error	95%CI	Z	P value
AFP	0.593	30.19	96.17	0.0481	(0.550, 0.634)	1.93	0.0538
CEA	0.611	32.08	96.00	0.0462	(0.551, 0.669)	1.197	0.2313
CA-199	0.608	75.47	42.86	0.0429	(0.548, 0.666)	2.511	0.0121
GGT	0.743	60.38	78.22	0.0380	(0.688, 0.794)	6.409	< 0.0001
Combined diagnosis	0.843	66.04	91.96	0.0319	(0.794, 0.883)	10.738	< 0.0001

AUC: Area under the curve; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA 19-9: Carbohydrate antigen 19-9; GGT: Gamma-glutamyl transferase.

Citation: Jiao HB, Wang W, Guo MN, Su YL, Pang DQ, Wang BL, Shi J, Wu JH. Evaluation of high-risk factors and the diagnostic value of alpha-fetoprotein in the stratification of primary liver cancer. World J Clin Cases 2022; 10(26): 9264-9275
URL: https://www.wjgnet.com/2307-8960/full/v10/i26/9264.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i26.9264